Drug Trials News for July 2011

Convergence Pharmaceuticals announces start of Phase II study for CNV1014802 Convergence Pharmaceuticals announces start of Phase II study for CNV1014802

Convergence Pharmaceuticals today announced that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.
19 July, 2011